US EditionStada lines up new chairman and board in preparation for IPO, source says
7 Articles
7 Articles
In 2017, financial investors took over the Hessian pharmaceutical manufacturer Stada. Now they are considering bringing the company, known for its cold remedies, back to the stock exchange. A new top manager is coming in for this.
The pharmaceutical company Stada was bought by financial investors in 2017, and its shares were taken off the stock exchange. The manufacturer then expanded its business and developed splendidly. The investors have been wanting to sell shares for some time. This could happen soon - in the form of another IPO.
Stada lines up new chairman and board in preparation for IPO, source says
By Emma-Victoria Farr FRANKFURT (Reuters) – Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug manufacturer ahead of a listing this year that could be one of Europe’s biggest, a person familiar with the matter told Reuters. Andreas Fibig, a Novo Nordisk board member, will become independent chairman of a board of nine members that will be established if the company go…
Badische Neueste Nachrichten
The Hessian pharmaceutical manufacturer, known for cold remedies, wants to return to the stock market in April and raise billions. To do this, Stada is bringing in a top manager.
Last year, the owners wanted to sell the pharmaceutical company Stada, but a deal failed due to the price. Now the Group should quickly go public - primarily to reduce debt.
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
